Fig. 4
From: Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy
Schematic of the planned AIM2CERV phase III study. FIGO, International Federation of Gynecologic Oncology; GOG, Gynecologic Oncology Group; IV, intravenous; Q, quarter